REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today
that National Institutes of Health (NIH) has awarded 12 research grants
totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of
these grants will be going to collaborators with whom RegeneRx is
working to understand its numerous biological activities and
capabilities in medical indications, including the role of Tβ4 as an
anti-inflammatory agent in tissue regeneration and its promotion of stem
cell maturation. Research on the identification and characterization of
the key factors needed to trigger stem cell differentiation and
maturation are among the most active areas of medical research and are
believed to be fundamental to the future development of breakthrough
therapeutic agents. Additional research projects are focused on
understanding the mechanisms of action and role of Tβ4 in diverse areas
of biomedicine ranging from cardiovascular disease and kidney fibrosis
to neurological disorders and memory. The research funded by these
grants will advance our understanding of the basic mechanisms of Tβ4’s
actions and its clinical potential.
“NIH grants are peer-reviewed with fewer than 20% of applicants
receiving this prestigious funding. These awards demonstrate the high
value that the scientific community and NIH place on both thymosin β4
technology and the research teams exploring its potential”
“NIH grants are peer-reviewed with fewer than 20% of applicants
receiving this prestigious funding. These awards demonstrate the high
value that the scientific community and NIH place on both thymosin β4
technology and the research teams exploring its potential,” stated Dr.
Hynda K. Kleinman, a scientist at the NIH for 31 years, who has served
on numerous grant review panels, and currently a consultant for RegeneRx
and a member of its scientific advisory board.
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients